Telehealth is rewriting how Americans access modern medicine.

The GLP-1 revolution is the most visible proof. Semaglutide and tirzepatide — both peptide-based compounds — have fundamentally reshaped how clinicians, endocrinologists, and researchers approach metabolic disease. The cardiovascular outcomes data from SURMOUNT and STEP trials didn’t just validate weight-loss mechanisms; they opened an entirely new clinical frame for what chronic disease management can look like when the biology is understood at the peptide level. What began as niche compounded formulations dispensed through 503A pharmacies is now a mainstream pharmaceutical category worth tens of billions annually. The trajectory from experimental to standard-of-care happened faster than almost anyone predicted, and it is not unique to GLP-1.

BPC-157 (Body Protection Compound-157) and TB-500 (Thymosin Beta-4) represent a parallel arc in musculoskeletal and connective tissue research. Both are synthetic derivatives of naturally occurring peptides, both have accumulated a meaningful body of preclinical literature examining tendon healing, angiogenesis, and inflammatory modulation, and both are actively studied in contexts ranging from sports-medicine recovery to post-surgical rehabilitation. They are not FDA-approved drugs — they exist in the research-grade and compounded pharmacy space — but the academic interest is serious and growing. Growth-hormone secretagogues like ipamorelin and sermorelin occupy a similar liminal zone: well-characterized pharmacology, clinician interest as alternatives to direct GH supplementation, and a regulatory status that sits somewhere between “unapproved” and “actively studied.” Understanding where the science actually is, vs. where the marketing claims it is, requires access to primary literature — which most patients do not have.

The FDA’s regulatory posture toward compounded peptides has been unusually turbulent. In 2023 and 2024, the agency moved to restrict access to several bulk peptides through 503A and 503B compounding pharmacies, citing insufficient evidence of clinical necessity. The industry pushed back; some compounds were delisted, then relisted, then subject to new guidance. For patients and clinicians navigating this landscape in real time, the information asymmetry is severe. A transparent, rigorously sourced educational platform — one that tracks the FDA docket, synthesizes the peer-reviewed literature, and explains the regulatory distinctions between 503A (patient-specific) and 503B (outsourcing facility) compounding — isn’t just useful. In this moment, it’s necessary. That is what TeleHealthcare is building.